1 C
London
Saturday, November 23, 2024
HomeBusinessRipple Therapeutics Announces Collaboration and Option-to-License Agreement with AbbVie to Develop Next-Generation...

Ripple Therapeutics Announces Collaboration and Option-to-License Agreement with AbbVie to Develop Next-Generation Therapies for Glaucoma Management

Date:

Related stories

Walters BBQ Proudly Offers Mouthwatering BBQ in Pittsburgh

Walters BBQ, a beloved Pittsburgh institution, is excited to...

GMZ Packaging Elevates Boba Tea Experience with Customizable Cups

Lids Built for Functionality GMZ understands the importance of a...

AME CEE 2025 Application Form Released for 2025-26 Session

1. Release of Application Form: 07th Oct, 2024 2. Application...

Pietro Pazzi Unveils the Leadership Chronicles Series

To view the orignal page, please visit - http://www.prlog.org/13039992-pietro-pazzi-unveils-the-leadership-chronicles-series.html WARNING -...

A-Team Group Names Winners of Its RegTech Insight Awards

 A-Team Group has announced the winners of its RegTech...

Ripple Therapeutics today announced a collaboration and option-to-license agreement with AbbVie to develop RTC-620, a next generation, fully biodegradable, sustained release drug delivery intracameral implant with repeat dosing capabilities to reduce intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT…

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories